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Background: The concept of sentinel lymph node surgery is to determine whether the cancer has spread to the
very first lymph node or sentinel node. If the sentinel node does not contain cancer, then there is a high likelihood
that the cancer has not spread to other lymph nodes. The sentinel node technique has been proven to be effective
in different types of cancer. In this study we want to determine whether a sentinel node procedure in patients with
ovarian cancer is feasible when the tracers are injected into the ovarian ligaments.
Methods/Design: Patients with a high likelihood of having an ovarian malignancy in whom a median laparotomy
and a frozen section analysis is planned and patients with endometrial cancer in whom a staging laparotomy is
planned will be included.
Before starting the surgical staging procedure, blue dye and radioactive colloid will be injected into the
ligamentum ovarii proprium and the ligamentum infundibulo-pelvicum. In the analysis we calculate the percentage
of patients in whom it is feasible to identify sentinel nodes. Other study parameters are the anatomical localization
of the sentinel node(s) and the incidence of false negative lymph nodes.
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Epithelial ovarian cancer (EOC) remains the tumor with
the most unfavorable prognosis within the field of the
gynecological oncology. The incidence of ovarian cancer
in the Netherlands in 2008 was 14.5 per 100,000 with
12.3 deaths per 100,000 [1]. In the United States in 2007
the incidence was 13.0 per 100,000 and there were 8.2
deaths per 100,000 [2]. The high mortality rate is par-
tially due to the fact that approximately 75% of patients
are diagnosed with advanced stage EOC.
EOC can metastasize through three different ways:
intraperitoneal (in the abdominal cavity), lymphogenous* Correspondence: r.kruitwagen@mumc.nl
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reproduction in any medium, provided the orand hematogenous [3,4]. Concerning the lymphogenous
spread, it is clear that lymphatic metastases of EOC
mainly occur in the para-aortic lymph nodes [5]. It is
believed that the tumor cells follow the lymph vessels
that accompany the ovarian artery and vein in the
infundibulopelvic ligament up to the high para-aortic re-
gion and renal vein. Nevertheless, pelvic lymph node
metastases are also frequently found [6-16]. These tumor
cells probably follow a different route, following the
para-uterine vessels in the broad ligament towards the
uterine artery and vein and further on to the iliac
vessels. In some case reports, isolated inguinal node me-
tastases are also described [17-20]. The exact mechanism
of this route of metastasis is still unclear, but the meta-
static cells might follow the course of the round liga-
ment towards the inguinal lymph nodes, or might follow
the iliac vessels towards the femoral vessels. The inci-
dence of lymph node metastasis in clinical stage I to IILtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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14.2%) [21].
In case of a clinical early stage ovarian cancer, the
Dutch guideline [1] recommends a staging laparotomy
with adequate lymph node sampling, with an absolute
minimum of ten lymph nodes removed. In the same
guideline, a footnote is made stating that a larger num-
ber of removed lymph nodes will increase the chance of
finding metastases. These lymph nodes also need to be
sampled from different anatomical regions, of which the
most important are the para-aortic and paracaval region
between the renal vein and inferior mesenteric artery,
the common, internal and external iliac vessels and the
obturator fossa.
According to the International Federation of Gynecology
and Obstetrics (FIGO), EOC with lymph node metastases
is classified as FIGO stage IIIC disease, even in the absence
of peritoneal metastases [22]. In contrast to patients with
FIGO stage I ovarian cancer after a comprehensive staging
procedure, patients with a FIGO stage III ovarian cancer
are obliged to receive adjuvant chemotherapy. Therefore,
the recognition of lymph node metastases is of utmost
importance.
Surgical staging of EOC and the extent of lymph node
dissection differs greatly from center to center [20].
A recent review, published in 2011, showed an inci-
dence of 14.2% for lymph node metastasis in early EOC
[21]. The incidence is higher in grade 3 tumors (20.0%)
and the serous histological subtype (23.3%), whereas in
grade 1 and mucinous tumors the incidence is 4.0% and
2.6%, respectively.
The assessment of lymph nodes with the aid of radio-
logical techniques (computed tomography (CT) scan,
magnetic resonance imaging (MRI), positron emission
tomography (PET)) alone in EOC is insufficient; the sen-
sitivity and specificity for detection of lymph node me-
tastases with PET scan is 73.2% and 96.7%, with CT scan
42.6% and 95.0%, and with MRI 54.7% and 88.3%, re-
spectively [23].
To identify the involved lymph nodes different surgical
approaches exist, ranging from taking random lymph
nodes in different anatomical regions (lymph node sam-
pling) to a systematic lymphadenectomy [20]. A system-
atic lymphadenectomy can be considered as the gold
standard. However, such a radical procedure gives more
morbidity than lymph node sampling. These include the
formation of lymphocysts (up to 13.5%), nerve and vessel
injury (up to 4%), increased blood loss and increased op-
erating time [24].
With a sentinel node procedure the first node that
receives primary lymphatic flow can be identified (the
so-called sentinel node). The pathological examination is
an indication of the nodal status of the remaining nodes;
when the sentinel node is negative, one can presumethat the remaining nodes are also not involved. As a
consequence, the patient may be spared a radical
lymphadenectomy, and thus the associated morbidity [25].
The sentinel node technique has been proven effective
in different cancers such as breast cancer and malignant
melanoma. In gynecological tumors it has been shown to
be effective in vulvar cancer [26]. Currently, sentinel node
studies are being performed for cervical and uterine cancer,
and some cancer centers already routinely perform sentinel
node procedures for these gynecological cancers. Sentinel
node studies in ovarian cancer are scarce. Nyberg et al.
performed a study in 16 patients with high-risk uterine
cancer in whom technetium and blue dye were injected
into the right or left ovary [27]. Since patients with a
high-risk uterine cancer undergo a staging procedure
similar to that of patients with early stage ovarian cancer
(namely, a total abdominal hysterectomy (TAH) with
bilateral salpingo-oophorectomy (BSO) and a pelvic
and para-aortic lymphadenectomy), these patients were
selected to investigate whether injecting tracers in the
ovary would render sentinel nodes. After an incubation
time of 15 minutes, a sentinel node was detected in 15 out
of 16 patients. Negishi et al. used activated charcoal solu-
tion to identify ovarian lymphatics in 11 patients [12]. The
charcoal was injected into the cortex of the ovary. The
charcoal was deposited in (sentinel) lymph nodes of all
patients. In both studies the tracer was injected into the
ovary. Some authors claim that injecting in the ovary can
be difficult when bulky ovarian masses are present. Fur-
thermore, it is claimed that there is a risk of tumor dissem-
ination when tracers are injected into the ovarian capsule
[26]. In the current feasibility study, the injection of the
tracer is performed in the ovarian ligaments, not in the
ovarian cortex. This is to avoid spillage and to be as close
as possible to the draining lymph vessels in the ovarian
ligaments, irrespective of the size of the ovarian masses.
Therefore, in addition to including patients with high-risk
endometrial cancer, we also can include patients with an
enlarged ovary without risk of tumor dissemination.
Lymphatic mapping can be performed with blue dyes
as well as with radioactive isotopes; both can be injected
into the ovarian ligaments, which contain the main
routes of lymph drainage. After the incubation time the
sentinel nodes can be visualized by either colorization
(blue lymph nodes can be identified) and/or with a
gamma probe that detects the radioactive tracer [27]. In
breast cancer it has been shown that the detection rate
is highest when both radioactive isotope and blue dye
are combined [28,29].
The blue dyes can cause an allergic reaction, exhibited
with urticaria, erythema, hypotension and even cardio-
vascular collapse with bronchospasm [25]. However, the
incidence of allergic reactions is very low and varies
between 0.07 and 2.7% [30-32].
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care workers [33]. No allergic reactions have been
described due to the radioactive isotope.
Since lymph node metastases are found in 14.2% of
patients with clinical early stage ovarian cancer, this is a
clinically relevant study. Indeed, a sentinel node proce-
dure can prevent unnecessary radical lymph node dis-
section with the associated morbidity. It could also be
more accurate than at-random lymph node sampling
which is the current standard care in ovarian cancer in
the Netherlands.
This study is scientifically relevant since injecting
tracers in the ovarian ligaments can enhance our know-
ledge on the lymphatic routes and dissemination sites of
ovarian cancer, that is, the anatomical locations of the
lymph nodes most likely to be involved in ovarian can-
cer. Injection of tracer in the ovarian ligaments has, to
our knowledge, never been published.Methods/Design
The primary objective is to determine whether or not a
sentinel node procedure in patients with ovarian cancer
is feasible by injecting the tracers into the ovarian
ligaments instead of into the ovary itself. The secondary
objectives are the anatomical location(s) and number of
the sentinel node(s): detected peroperatively with blue
dye and with a gamma probe, and the detection of
residual lymph nodes 24 hours after surgery with
scintigraphy.
In this feasibility study we will include both patients
who are believed to have a malignant ovarian tumor
as well as patients with a high-grade uterine carci-
noma. The latter group of patients can also be
included because these patients undergo the same
surgical procedure: TAH with BSO and a pelvic
and para-aortic lymphadenectomy or lymph node
sampling.
The study will end when 20 evaluable patients are
included, of which at least ten patients have ovarian
cancer. The expected inclusion period is estimated to
be two years. If the detection rate of the sentinel
node is less than 50%, or when fewer than five
patients are included in a year, the study will be
ended prematurely.
The study will be performed in the Maastricht Univer-
sity Medical Centre. Patients who are believed to have a
malignant ovarian tumor planned for exploratory lapar-
otomy will be asked to participate in the study. When a
malignancy is confirmed on frozen section, the sentinel
nodes will be removed prior to proceeding with a
complete staging procedure. Patients with endometrial
cancer in whom a staging laparotomy is planned will
also be asked to participate.Inclusion criteria
1. Patients with a high likelihood of having a
malignant ovarian tumor planned for exploratory
laparotomy.
2. Patients with high-grade endometrial cancer for
whom a staging laparotomy is planned.
3. Age 18 to 85 years.
Exclusion criteria
1. Previous surgery on one or both ovaries.
2. Previous vascular surgery of the aorta, caval vein,
and/or iliac vessels.
3. Previous lymphadenectomy or lymph node sampling
in the iliac or para-aortic region.
4. History of a malignant lymphoma.
5. History of a malignant tumor in the abdominal
cavity.
6. Previous allergic reaction to blue dye or human
albumin.
7. Pregnant or lactating patients.
Sample size calculation
Between 24 and 28 patients will be included in the study.
The sample size calculation is based on the fact that:
1. With a group of 20 evaluable patients the study
group is large enough to give an answer on whether
sentinel node(s) can be detected related to the
ovarian lymphatic flow when the tracers are injected
into the ovarian ligaments. For this purpose, patients
with either an ovarian and / or endometrial
malignancy and who are planned for a staging
laparotomy can and will be included.
2. Patients with a benign result on a frozen section of
the suspicious ovary will be excluded from the study
because no lymph node(s) will be resected in these
patients. These patients will also be documented and
described in the report.
3. Based on retrospective data, for 60% of the patients
with a suspicious ovary, the frozen section will
confirm a ovarian malignancy.
4. To calculate one of the secondary endpoints
(incidence of false negative sentinel lymph node) at
least 10 patients with ovarian cancer should be part
of the 20 evaluable patients.
Surgical procedure
Patients with a high likelihood of having a malignant
ovarian tumor
After making the median incision and opening the abdo-
men, before starting with removal of the enlarged and
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will be injected into the ligamentum ovarii proprium
(median side) and into the ligamentum infundibulo-
pelvicum (lateral side), close to the ovary and just below
the peritoneum. Therefore, an injection of blue dye
(0.5 mL) will be given ventrally and dorsally in the
ligamentum ovarii proprium and the ligamentum
infundibulo-pelvicum (total amount 2.0 mL). The same
will be done with the radioactive isotope, with each
injection of 0.5 mL containing a dose of 20-MBq
technetium-99-m-labeled albumin nanocolloid (99mTc-
nanocolloid or NanocollW, GE Healthcare, Eindhoven,
The Netherlands). A 15-minute interval will be planned
after injection. The exact time interval for detection of
positive nodes is unclear. Common practice is to wait
for 15 minutes; if in this time period the node is not
detected, it is considered negative. In daily practice a
wait of more than 15 minutes during surgery is not feas-
ible. At 5 and 10 minutes the radioactivity will be
measured along the lymphatic tract to document
whether or not sentinel node(s) can be identified at a
shorter time interval in future studies. A gamma probe
measures the radioactivity. The gamma probe will be the
same device in all surgical procedures.
After the 15 minutes time interval the ovarian mass will
be removed and presented to the pathologist for a frozen
section. If the result is benign, no further actions will be
performed in these patients. If the result is malignant, the
sentinel node(s) will be identified either (once more) by
the radioactive tracer and / or visually (blue dye) after
opening the retroperitoneal space. After removal of the
sentinel node(s) a complete standard staging procedure
will be performed including a comprehensive sampling of
other lymph nodes at the different locations.Figure 1 Locations of the sentinel nodes resected.Patients with endometrial cancer for whom a staging
laparotomy is planned
After making the median incision and opening the
abdomen, blue dye and the radioactive isotope will be
injected into the ligamentum ovarii proprium (median
side) and the ligamentum infundibulo-pelvicum (lateral
side) of one of the ovaries, in the same manner as
decribed above in patients for whom there is a high sus-
picion of an ovarian malignancy. The choice of the ovary
(left or right side) will alter between left and right by
each patient who is included in the study.
A 15-minute interval will be planned after injection. In
this time period at 5 and 10 minutes the radioactivity
will be measured along the lymphatic tract to document
whether or not perhaps sentinel node(s) can be identi-
fied at a shorter time-interval in future studies. The
radioactivity is measured by a gamma probe. The
gamma probe will be the same device in all surgeries.After the 15 minutes time-interval the surgical staging
procedure starts with a TAH and BSO. After approximately
45 minutes the sentinel node(s) will be identified either
(once more) by the radioactive tracer and / or visually
(blue dye) after opening the retroperitoneal space. This
45 minutes time interval is chosen to mimic the time
interval when a frozen section is performed in case of
an ovarian tumor. After removal of the sentinel node(s)
a complete standard staging procedure will be
performed including a comprehensive at random sam-
pling of other lymph nodes at the different locations.
After surgery
Depending on the mobility of the patient, a scintigram
will be performed 24 hours after surgery at the nuclear
department. This scintigram is performed to detect any
residual radioactive hot spots. If there is any residual
radioactivity this may indicate that sentinel nodes have
not been identified during surgery and this therefore
gives an indication of the reliability of identifying senti-
nel nodes during surgery.Data collection
Patient characteristics
The following information will recorded:
1. Age
2. Surgical findings: tumor side, injection site, time
between injection and detection, the number of
detected sentinel nodes, anatomical location of
sentinel nodes, intensity (gamma counts) of
radioactive nodes, complications during surgery,
side effects during surgery.
Kleppe et al. Trials 2013, 14:47 Page 5 of 6
http://www.trialsjournal.com/content/14/1/473. Histology: results of the frozen section, tumor type
(ovarian or endometrial), differentiation grade,
histological results of sentinel and non-sentinel
nodes.
4. FIGO stage
5. Postoperative scintigram, residual nodes, location of
residual nodes.
The surgeon has to register the number and location of
sentinel nodes resected. For this purpose the surgeon has
to draw the location of the lymph nodes in an anatomical
drawing (Figure 1). Twelve different locations will be used
to report where the sentinel nodes were found:
1. High para-aortic (left side of the aorta between left
renal vein and lower mesenteric artery)
2. Low para-aortic (left side of the aorta below the
lower mesenteric artery)
3. High interaortacaval (between aorta and caval vein
and between left renal vein and lower mesenteric
artery)
4. Low interaortacaval (between aorta and caval vein
and below the lower mesenteric artery
5. High para-caval (right side of the caval vein and
between right renal vein and above the level of the
lower mesenteric artery)
6. Low para-caval (right side of the caval vein and
below the level of the lower mesenteric artery)
7. Iliaca communis left
8. Illaca communis right
9. External iliaca left
10. External iliaca right
11. Obturator left
12. Obturator right
The surgeon also has to register the location of the
lymphatic tissue removed, related to the lymph node
sampling following the removal of the sentinel node(s).
Withdrawal of individual subjects and replacement
Subjects can leave the study at any time for any reason if
they wish to do so without any consequences. The inves-
tigator can decide to withdraw a subject from the study
for urgent medical reasons. Patients with a benign ovar-
ian tumor on frozen section during surgery will also be
excluded from the study. These patients will be replaced
by a new study subject until 20 completed sentinel node
procedures are performed.
Discussion
Recognition of sentinel nodes with blue dye and the
gamma probe during surgery is less reliable than by
making a scintigram. Therefore ideally, as in breast and
vulvar cancer, a scintigram is made before surgery torecognize the sentinel nodes so that during surgery
no sentinel nodes will be missed. This cannot be
accomplished in patients with ovarian cancer, because
the tracers are injected during surgery. However, we ex-
pect that missing sentinel nodes in patients with ovarian
cancer occurs less frequently because the area where the
sentinel nodes can occur can easily be visualized. Never-
theless, by making a scintigram 24 hours after surgery,
at least an impression is obtained on the incidence of
unrecognized sentinel lymph nodes.
Trial status
Approved by the Medical Ethical Committee Maastricht
University Hospital, University of Maastricht. Open for
inclusion.
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